RESEARCH PROFILE
KPV
Alpha-MSH Derived Tripeptide • Inflammatory & Gut Barrier Research
KPV is a three amino acid peptide derived from the C-terminal region of alpha-melanocyte-stimulating hormone. Research has focused on inflammatory signaling, intestinal barrier biology, antimicrobial activity, and immune modulation.
Most of the evidence remains preclinical, with no completed human clinical trial establishing therapeutic efficacy or an approved dosing regimen.
INVESTIGATIONAL • NOT FDA APPROVED • PRECLINICAL EVIDENCE
KPV AT A GLANCE
Category
Anti-inflammatory and gut-barrier research peptide
Full Sequence
Lysine • Proline • Valine
Origin
C-terminal tripeptide of alpha-MSH
Primary Research Focus
Inflammation • Gut barrier • Immune signaling • Antimicrobial activity
Evidence Base
Primarily animal and laboratory research
Human Evidence
No completed human clinical trial identified in the Project source
Regulatory Status
Not FDA approved
IMPORTANT DISTINCTION
KPV is derived from alpha-MSH, but it does not reproduce all of alpha-MSH's biological effects.
Unlike melanocortin peptides associated with pigmentation, KPV does not appear to stimulate melanocortin-receptor signaling responsible for tanning or pigment production.
Your Project source specifically notes that KPV's research profile is centered on anti-inflammatory, barrier, and antimicrobial mechanisms, not pigmentation.
WHAT IS KPV?
KPV is a short peptide consisting of three amino acids:
Lysine • Proline • Valine
It is derived from the C-terminal portion of alpha-melanocyte-stimulating hormone, or alpha-MSH.
Alpha-MSH is a naturally occurring peptide involved in melanocortin signaling, pigmentation, inflammation, and immune regulation.
KPV represents only a very small fragment of that larger peptide.
Despite its small size, preclinical research suggests KPV may retain some of the anti-inflammatory properties associated with alpha-MSH while not activating the same melanocortin pathways involved in pigmentation.
Research has examined KPV in relation to:
Intestinal inflammation
Gut-barrier biology
NF-κB signaling
Immune regulation
Antimicrobial activity
Inflammatory skin and epithelial models
An unusual feature of KPV is that its small size may allow transport through the intestinal peptide transporter PepT1, which has made oral and gastrointestinal research particularly relevant.
MECHANISM OF ACTION
KPV appears to act through several anti-inflammatory and barrier-related mechanisms identified primarily in animal and laboratory studies.
PepT1-MEDIATED UPTAKE
One of the best-described mechanisms in your Project source involves PepT1, a peptide transporter expressed on intestinal epithelial cells.
PepT1 normally transports small dipeptides and tripeptides from the intestinal lumen into cells.
Because KPV is a tripeptide, it can be transported through this pathway.
In inflammatory conditions, PepT1 expression may increase, potentially allowing greater local uptake of KPV into inflamed intestinal tissue.
NF-κB INHIBITION
Preclinical research suggests KPV can reduce activation of NF-κB, a major transcription factor involved in inflammatory gene expression.
NF-κB helps regulate production of many inflammatory mediators.
Reducing this pathway may help explain the anti-inflammatory effects observed in experimental models.
MAP KINASE SIGNALING
Your Project source also identifies suppression of MAP kinase signaling in experimental systems.
This pathway participates in inflammatory responses, cellular stress, and immune signaling.
CYTOKINE SIGNALING
Experimental research has reported reductions in inflammatory signaling associated with mediators such as:
TNF-related pathways
Other pro-inflammatory cytokine systems
These findings remain primarily preclinical.
ANTIMICROBIAL ACTIVITY
Laboratory research cited in the Project profile has reported direct antimicrobial activity against organisms including:
Staphylococcus aureus
Candida albicans
This is in-vitro evidence and should not be interpreted as proof that KPV treats infection in humans.
NOT MELANOCORTIN-RECEPTOR DEPENDENT
Your Project source emphasizes that KPV's anti-inflammatory effects appear to persist even when melanocortin receptor pathways are disrupted.
This supports the view that KPV works through mechanisms distinct from the pigmentation-related effects of full-length alpha-MSH.
WHAT THE RESEARCH SHOWS
NO COMPLETED HUMAN CLINICAL TRIAL
The most important evidence limitation is straightforward:
Your Project source identifies no completed human clinical trial evaluating KPV.
There is no published human dose-finding program establishing:
Clinical efficacy
Optimal dose
Best route of administration
Long-term safety
Treatment duration
Therapeutic indication
INFLAMMATORY BOWEL DISEASE MODELS
A major area of preclinical interest involves intestinal inflammation.
Research cited in your Project source showed that orally delivered KPV reduced disease severity in animal models of inflammatory bowel disease.
The PepT1 transporter was identified as an important component of this effect.
COLON-TARGETED DELIVERY
Your Project source also cites nanoparticle-based research designed to deliver KPV to inflamed colonic tissue.
These systems improved targeting to areas of intestinal inflammation and reduced inflammatory markers in experimental models.
This work supports the idea that local delivery and route may matter significantly for KPV research.
EPITHELIAL INFLAMMATION
Cell studies have reported dose-dependent suppression of inflammatory signaling in bronchial epithelial models.
This supports a broader anti-inflammatory research profile beyond the gastrointestinal tract.
ANTIMICROBIAL RESEARCH
Laboratory experiments reported antimicrobial effects against:
S. aureus
C. albicans
These findings are useful mechanistically but are not equivalent to clinical infection-treatment evidence.
ALPHA-MSH RELATED RESEARCH
KPV belongs to a larger research family involving alpha-MSH-derived peptides.
Reviews cited in the Project profile discuss melanocortin-related anti-inflammatory signaling and the broader immunomodulatory activity of this peptide family.
WHAT THE EVIDENCE SUPPORTS
The Project evidence supports continued research into:
Intestinal inflammatory signaling
PepT1 transport
NF-κB suppression
Barrier-related biology
Antimicrobial activity
Immune modulation
WHAT HAS NOT BEEN ESTABLISHED
There is no completed human trial establishing KPV as an effective treatment for:
Inflammatory bowel disease
Crohn's disease
Ulcerative colitis
Autoimmune disease
Skin inflammation
Chronic inflammatory disorders
Infection
Gut permeability disorders
IMPORTANT EVIDENCE LIMITATION
Animal and laboratory findings are promising mechanistically, but they do not establish therapeutic effectiveness in humans.
The Project source explicitly warns against presenting KPV as a proven treatment or cure for inflammatory disease.
SAFETY & RESEARCH CONSIDERATIONS
KPV's human safety profile is not established because there are no completed human clinical trials defining adverse-event rates, long-term effects, or dose-related toxicity.
COMMUNITY-REPORTED EFFECTS
Your Project profile notes community reports such as:
Mild transient injection-site irritation
Occasional mild headache
These observations are anecdotal and should not be treated as a validated safety database.
PIGMENTATION
KPV is generally considered non-pigmenting in the preclinical literature.
The Project source notes that KPV does not appear to bind or activate melanocortin receptors in the same way as pigmentation-related melanocortin peptides.
IMMUNE MODULATION
Because KPV is studied for anti-inflammatory and immune-modulating effects, there is a theoretical concern that repeated or excessive exposure could alter immune signaling in ways that are not yet understood.
Long-term human consequences have not been established.
AUTOIMMUNE DISEASE & IMMUNOSUPPRESSION
Your Project profile advises caution when KPV is discussed alongside:
Autoimmune conditions
Immunosuppressive medications
Significant chronic inflammatory disease
These contexts can involve complex immune regulation and should not be reduced to peptide-level assumptions.
PREGNANCY & LACTATION
There are no established human safety data for pregnancy or breastfeeding.
PRODUCT QUALITY
Research-use peptide quality remains an independent risk.
Potential concerns include:
Incorrect identity
Incorrect concentration
Contamination
Degradation
Sterility failure
Lot-to-lot variability
Analytical testing can characterize a specific tested sample but cannot establish overall clinical safety.
REGULATORY CONTEXT
KPV IS NOT FDA APPROVED
KPV is not an FDA-approved drug for any indication.
There is no FDA-approved branded KPV product.
FDA COMPOUNDING REVIEW
Your Project source documents FDA review activity involving KPV.
Materials prepared for a July 2026 Pharmacy Compounding Advisory Committee meeting proposed that KPV free base and KPV acetate not be added to the 503A Bulks List.
The Project source identifies concerns including limited human evidence and insufficient support for routine compounded clinical use.
IMPORTANT REGULATORY DISTINCTION
A Pharmacy Compounding Advisory Committee review is not the same as FDA approval or final drug approval.
Likewise:
Compounding eligibility does not equal efficacy
Research availability does not equal medical suitability
Preclinical evidence does not establish an approved indication
ANTI-DOPING STATUS
Your Project source notes that KPV itself is not specifically named on the WADA Prohibited List.
However, because it is derived from alpha-MSH-related biology and because anti-doping rules can change, athletes should review current WADA rules and governing-body requirements.
RESEARCH STATUS
KPV should therefore be described as an investigational research peptide with primarily preclinical evidence.
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation only for specific samples and lots that can be matched to corresponding laboratory reports.
LOT SPECIFIC ANALYTICAL DOCUMENTATION
Analytical documentation is displayed only when Croix has a corresponding laboratory report that can be matched to the specific product and lot.
No matching KPV COA is currently displayed.
IMPORTANT COA LIMITATION
When analytical documentation becomes available, results should apply only to the specific sample identified in the corresponding laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix requires the product, strength, lot or batch, sample ID, laboratory, and report date to be matched before analytical documentation is represented as supporting a product.
A passing COA does not establish FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated lots.
SELECTED RESEARCH & REFERENCES
Dalmasso G, Charrier-Hisamuddin L, et al.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Gastroenterology. 2008.
Preclinical research identifying PepT1-mediated intestinal transport as a central mechanism.
Xiao B, Laroui H, et al.
Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis.
Molecular Therapy. 2017.
Preclinical colon-targeted KPV delivery research.
Kannengiesser K, et al.
Research examining KPV and TNF-driven inflammatory signaling in bronchial epithelial models.
Cell-based inflammatory signaling research.
Catania A, et al.
Research examining direct antimicrobial activity associated with alpha-MSH-derived peptides.
Laboratory antimicrobial evidence.
Brzoska T, Luger TA, Maaser C, et al.
Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.
Annals of the Rheumatic Diseases. 2008.
Review of alpha-MSH-related peptide biology.
Getting SJ.
Research reviewing melanocortin receptors and anti-inflammatory pharmacology.
Useful for distinguishing KPV from full-length melanocortin signaling.
Lee DJ, Woony JY, et al.
Research examining melanocortin peptides in inflammatory bowel disease.
Wang W, et al.
Review of melanocortin regulation of inflammation.
Star RA, Rajora N, et al.
Research examining alpha-MSH and macrophage nitric-oxide signaling.
Rajora N, Boccoli G, et al.
Preclinical alpha-MSH inflammatory bowel disease research.
Lipton JM, et al.
Research examining anti-inflammatory effects of alpha-MSH in acute, chronic, and systemic inflammation.
U.S. Food & Drug Administration
Pharmacy Compounding Advisory Committee materials concerning KPV free base and KPV acetate.
EVIDENCE NOTE
KPV has a coherent and biologically plausible preclinical research profile involving:
PepT1-mediated intestinal uptake
NF-κB signaling
Inflammatory cytokines
Barrier biology
Antimicrobial activity
However, no completed human clinical trial cited in the Project source establishes KPV as a clinically effective anti-inflammatory or gastrointestinal therapy.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish KPV as safe or effective for personal use.
KPV is an investigational alpha-MSH-derived tripeptide studied primarily in animal and laboratory models involving intestinal inflammation, barrier function, immune signaling, and antimicrobial activity.
KPV is not FDA approved for any therapeutic indication, and there is no completed human clinical trial establishing efficacy, optimal dosing, route, or long-term safety.
Animal and laboratory findings involving inflammatory bowel disease, gut-barrier biology, immune modulation, or antimicrobial activity should not be interpreted as established clinical benefits in humans.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.